Publication:
Depot‐medroxyprogesterone acetate (DMPA) and risk of liver cancer

Issued Date

1991-01-01

Resource Type

Article

ISSN

10970215
00207136

DOI

10.1002/ijc.2910490206

Other identifier(s)

2-s2.0-0025815286

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

International Journal of Cancer. Vol.49, No.2 (1991), 182-185

Suggested Citation

J. G. Mati, P. Kenya, A. Kungu, D. Gatei, Suporn Silpisoronkosol, Tieng Pardthaisong, Virote Sahapong, Choti Theetranont, Banpot Boosiri, Supawat Chutivongse, Pramuan Virutmasen, Chansuda Wongsrchanalai, Sermsri Sindhvananda, Suporn Koetsawang, Daungdao Rachawat, Amom Koetsawang, P. P. Anthony, David B. Thomas, Elizabeth A. Noonan, Roberta M. Ray, Karin A. Rosenblatt, Janet L. Stanford, Susan Holck, Timothy M.M. Farley, Karin A. Rosenblatt, David B. Thomas Depot‐medroxyprogesterone acetate (DMPA) and risk of liver cancer. International Journal of Cancer. Vol.49, No.2 (1991), 182-185. doi:10.1002/ijc.2910490206 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/22015

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Depot‐medroxyprogesterone acetate (DMPA) and risk of liver cancer

Author(s)

J. G. Mati
 P. Kenya
 A. Kungu
 D. Gatei
 Suporn Silpisoronkosol
 Tieng Pardthaisong
 Virote Sahapong
 Choti Theetranont
 Banpot Boosiri
 Supawat Chutivongse
 Pramuan Virutmasen
 Chansuda Wongsrchanalai
 Sermsri Sindhvananda
 Suporn Koetsawang
 Daungdao Rachawat
 Amom Koetsawang
 P. P. Anthony
 David B. Thomas
 Elizabeth A. Noonan
 Roberta M. Ray
 Karin A. Rosenblatt
 Janet L. Stanford
 Susan Holck
 Timothy M.M. Farley
 Karin A. Rosenblatt
 David B. Thomas

Other Contributor(s)

Chiang Mai University
 Chulalongkorn University
 Mahidol University
 N. and East Devon Health Authority
 Fred Hutchinson Cancer Research Center
 Organisation Mondiale de la Sante

Abstract

A hospital‐based case‐control study was conducted to assess the possible relationship between use of depot‐medroxy‐progesterone acetate (DMPA), an injectable progestational contraceptive, and the development of liver cancer in 2 developing countries where hepatitis B is endemic. Information about prior DMPA use and potential confounders was ascertained during personal interviews with 71 cases and 530 controls from 3 hospitals in Thailand and 1 hospital in Kenya. No significant association between liver cancer and DMPA use was observed in Kenya (RR = 1.64, 95% CI = 0.4‐0.6) or Thailand (RR = 0.33, 95% CI = 0.1‐1.O). No consistent changes in risk were observed with duration of use, time since last use, or time since first use. No significant associations were observed between DMPA use and risks of either hepatocellular carcinoma or cholangiocarcinoma. These findings suggest that risk of liver cancer in areas where hepatitis B is endemic is not appreciably altered by the use of DMPA. Copyright © 1991 Wiley‐Liss, Inc., A Wiley Company

Keyword(s)

Biochemistry, Genetics and Molecular Biology
 Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/22015

Collections

Scopus 1991-2000